NATERA ($NTRA) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of -$0.47 per share, beating estimates of -$0.50 by $0.03. The company also reported revenue of $752,750,000, beating estimates of $673,900,576 by $78,849,424.
Stock price change since market close: +15.31%
You can see Quiver Quantitative's $NTRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NATERA Insider Trading Activity
NATERA insiders have traded $NTRA stock on the open market 251 times in the past 6 months. Of those trades, 0 have been purchases and 251 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 52 sales selling 311,157 shares for an estimated $62,296,323.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 33 sales selling 73,355 shares for an estimated $17,762,965.
- ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 66,283 shares for an estimated $14,704,918.
- JONATHAN SHEENA has made 0 purchases and 64 sales selling 27,456 shares for an estimated $5,924,959.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 33 sales selling 25,778 shares for an estimated $5,815,846.
- HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 17 sales selling 12,502 shares for an estimated $2,826,537.
- GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 8 sales selling 6,132 shares for an estimated $1,359,815.
- ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 3,221 shares for an estimated $702,984.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
NATERA Hedge Fund Activity
We have seen 412 institutional investors add shares of NATERA stock to their portfolio, and 350 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,312,887 shares (+12.1%) to their portfolio in Q1 2026, for an estimated $262,564,271
- FMR LLC added 1,078,266 shares (+73.1%) to their portfolio in Q1 2026, for an estimated $215,642,417
- FARALLON CAPITAL MANAGEMENT LLC removed 707,000 shares (-18.1%) from their portfolio in Q1 2026, for an estimated $141,392,930
- DUQUESNE FAMILY OFFICE LLC added 552,249 shares (+22.0%) to their portfolio in Q1 2026, for an estimated $110,444,277
- CASTLE HOOK PARTNERS LP added 361,941 shares (+16.7%) to their portfolio in Q1 2026, for an estimated $72,384,580
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 341,574 shares (-54.6%) from their portfolio in Q1 2026, for an estimated $68,311,384
- MAPLELANE CAPITAL, LLC added 339,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $67,796,610
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
NATERA Government Contracts
We have seen $504,900 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
- NEXT GENERATION SEQUENCING AND PERIPHERAL BLOOD CTDNA TESTING SERVICES (RESEARCH): $7,000
- GENETIC TESTING: $3,300
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
NATERA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/23/2026
- William Blair issued a "Outperform" rating on 04/14/2026
To track analyst ratings and price targets for NATERA, check out Quiver Quantitative's $NTRA forecast page.
NATERA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 12 analysts offer price targets for $NTRA in the last 6 months, with a median target of $270.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
- Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
- Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
- Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
- Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
- Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
